Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2017 Feb 8

PMID 28167928

Citations 383

Authors

Arun Chaudhury

Chitharanjan Duvoor

Vijaya Sena Reddy Dendi

Shashank Kraleti

Aditya Chada

Rahul Ravilla

Asween Marco

Nawal Singh Shekhawat

Maria Theresa Montales

Kevin Kuriakose

Appalanaidu Sasapu

Alexandria Beebe

Naveen Patil

Chaitanya K Musham

Govinda Prasad Lohani

Wasique Mirza

Affiliations

Soon will be listed here.

Abstract

Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation (http://www.diabetesatlas.org/). Diabetes mellitus is a chronic, progressive, incompletely understood metabolic condition chiefly characterized by hyperglycemia. Impaired insulin secretion, resistance to tissue actions of insulin, or a combination of both are thought to be the commonest reasons contributing to the pathophysiology of T2DM, a spectrum of disease originally arising from tissue insulin resistance and gradually progressing to a state characterized by complete loss of secretory activity of the beta cells of the pancreas. T2DM is a major contributor to the very large rise in the rate of non-communicable diseases affecting developed as well as developing nations. In this mini review, we endeavor to outline the current management principles, including the spectrum of medications that are currently used for pharmacologic management, for lowering the elevated blood glucose in T2DM.

Citing Articles

Evaluating diabetes-related nutrition knowledge and dietary beliefs among type 2 diabetes patients in Vidarbha region, Maharashtra: a mixed method approach for insightful analysis.

Kawalkar U, Mankar A, Puri M, Singh A, Telrandhe S, Gaidhane A Front Nutr. 2025; 12:1420662.

PMID: 40066153 PMC: 11891037. DOI: 10.3389/fnut.2025.1420662.

Therapeutic potential of extract by experimental and computational approaches: phenolic content and bioactivities for antioxidant, antidiabetic, and anticholinergic properties.

Altin S, Isik M, Alp C, Dikici E, Koksal E, Kirboga K Front Chem. 2025; 13:1541250.

PMID: 40046016 PMC: 11880275. DOI: 10.3389/fchem.2025.1541250.

Integrated in vitro, in silico, and in vivo approaches to elucidate the antidiabetic mechanisms of Cicer arietinum and Hordeum vulgare extract and secondary metabolites.

Shahzad A, Liu W, Hussain S, Ni Y, Cui K, Sun Y Sci Rep. 2025; 15(1):6620.

PMID: 39994296 PMC: 11850774. DOI: 10.1038/s41598-025-89642-5.

Administration of a Next-Generation Probiotic Nissle 1917-GLP-1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes.

Luo J, Fang Y, Qi Z, Cui F, Hu H, Li S Can J Infect Dis Med Microbiol. 2025; 2025:6675676.

PMID: 39949529 PMC: 11824388. DOI: 10.1155/cjid/6675676.

The antidiabetic effect of safflower yellow by regulating the GOAT/ghrelin/GHS-R1a/cAMP/TRPM2 pathway.

Ma Y, Zhang H, Yan Q, Wang P, Guo W, Yu L Sci Rep. 2025; 15(1):5037.

PMID: 39934157 PMC: 11814266. DOI: 10.1038/s41598-025-87201-6.

References

Taylor S, Harris K . The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy. 2013; 33(9):984-99. DOI: 10.1002/phar.1303. View

Al-Arouj M, Bouguerra R, Buse J, Hafez S, Hassanein M, Ibrahim M . Recommendations for management of diabetes during Ramadan. Diabetes Care. 2005; 28(9):2305-11. DOI: 10.2337/diacare.28.9.2305. View

Fogelman Y, Kitai E, Blumberg G, Golan-Cohen A, Rapoport M, Carmeli E . Vitamin B12 screening in metformin-treated diabetics in primary care: were elderly patients less likely to be tested?. Aging Clin Exp Res. 2016; 29(2):135-139. DOI: 10.1007/s40520-016-0546-1. View

Palmer S, Mavridis D, Nicolucci A, Johnson D, Tonelli M, Craig J . Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. JAMA. 2016; 316(3):313-24. DOI: 10.1001/jama.2016.9400. View

Koch L . Obesity: Teaching an old drug new tricks--amlexanox targets inflammation to improve metabolic dysfunction. Nat Rev Endocrinol. 2013; 9(4):185. DOI: 10.1038/nrendo.2013.42. View

Umpierre D, Ribeiro P, Kramer C, Leitao C, Zucatti A, Azevedo M . Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011; 305(17):1790-9. DOI: 10.1001/jama.2011.576. View

Inzucchi S, Lipska K, Mayo H, Bailey C, McGuire D . Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014; 312(24):2668-75. PMC: 4427053. DOI: 10.1001/jama.2014.15298. View

Ismail-Beigi F . Pathogenesis and glycemic management of type 2 diabetes mellitus: a physiological approach. Arch Iran Med. 2012; 15(4):239-46. DOI: 012154/AIM.0014. View

Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F . Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2011; 122(6):253-70. PMC: 3398862. DOI: 10.1042/CS20110386. View

10.

Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D . Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med. 2009; 57(3):495-9. DOI: 10.2310/JIM.0b013e318197ec8b. View

11.

Siraj E, Rubin D, Riddle M, Miller M, Hsu F, Ismail-Beigi F . Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. Diabetes Care. 2015; 38(11):2000-8. PMC: 4876773. DOI: 10.2337/dc15-0598. View

12.

Maruthur N, Tseng E, Hutfless S, Wilson L, Suarez-Cuervo C, Berger Z . Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016; 164(11):740-51. DOI: 10.7326/M15-2650. View

13.

Garber A, Abrahamson M, Barzilay J, Blonde L, Bloomgarden Z, Bush M . CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract. 2016; 22(1):84-113. DOI: 10.4158/EP151126.CS. View

14.

Reilly S, Chiang S, Decker S, Chang L, Uhm M, Larsen M . An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice. Nat Med. 2013; 19(3):313-21. PMC: 3594079. DOI: 10.1038/nm.3082. View

15.

Nathan D, Buse J, Davidson M, Ferrannini E, Holman R, Sherwin R . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008; 32(1):193-203. PMC: 2606813. DOI: 10.2337/dc08-9025. View

16.

Tuso P . Prediabetes and lifestyle modification: time to prevent a preventable disease. Perm J. 2014; 18(3):88-93. PMC: 4116271. DOI: 10.7812/TPP/14-002. View

17.

Nauck M, Meier J . The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016; 4(6):525-36. DOI: 10.1016/S2213-8587(15)00482-9. View

18.

Nathan D, Buse J, Kahn S, Krause-Steinrauf H, Larkin M, Staten M . Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013; 36(8):2254-61. PMC: 3714493. DOI: 10.2337/dc13-0356. View

19.

Ferrannini E, DeFronzo R . Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015; 36(34):2288-96. DOI: 10.1093/eurheartj/ehv239. View

20.

Nyenwe E, Kitabchi A . The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism. 2016; 65(4):507-21. DOI: 10.1016/j.metabol.2015.12.007. View